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Abstract
Background: It is hypothesized that dietary linoleic acid (LA) promotes chronic and acute diseases in humans by
enriching tissues with arachidonic acid (AA), its downstream metabolite, and dietary studies with rodents have
been useful for validation. However, levels of LA in research diets of rodents, as published in the literature, are
notoriously erratic making interspecies comparisons unreliable. Therefore, the ability to extrapolate the biological
effects of dietary LA from experimental rodents to humans necessitates an allometric scaling model that is rooted
within a human equivalent context.
Methods: To determine the physiological response of dietary LA on tissue AA, a mathematical model for
extrapolating nutrients based on energy was used, as opposed to differences in body weight. C57BL/6J mice were
divided into 9 groups fed a background diet equivalent to that of the US diet (% energy) with supplemental doses
of LA or AA. Changes in the phospholipid fatty acid compositions were monitored in plasma and erythrocytes and
compared to data from humans supplemented with equivalent doses of LA or AA.
Results: Increasing dietary LA had little effect on tissue AA, while supplementing diets with AA significantly
increased tissue AA levels, importantly recapitulating results from human trials.
Conclusions: Thus, interspecies comparisons for dietary LA between rodents and humans can be achieved when
rodents are provided human equivalent doses based on differences in metabolic activity as defined by energy
consumption.

Background
As surrogates for human inquisition, animal models
reside at the core of medical innovation. Through careful environmental control, these genetically similar models facilitate therapeutic advancements in the magnitude
of human disease. Rodent dietary composition is of particular interest in the field of nutrition research as it
provides a way to assess the translational ability of individual dietary constituents, through appropriate dosing
of nutrients, to physiological effects observed in humans
consuming similar levels of nutrients.
Dietary profiles of n-6 polyunsaturated fatty acid
(PUFA), linoleic acid (LA) and the relationship to chronic
and acute diseases, in both rodents and humans, appears
* Correspondence: jwhelan@utk.edu
Department of Nutrition, 1215 West Cumberland Avenue, 229 Jessie Harris
Building, University of Tennessee, Knoxville, TN 37996-1920, USA

to lie in tissue enrichment of the downstream metabolite,
arachidonic acid (AA) [1-3]. It is hypothesized that metabolism of dietary AA produces bioactive compounds
called eicosanoids that are positively correlated with the
appreciation of tissue AA [4]. While the relationship of
AA and eicosanoids is well established, the response to
dietary LA on changes in tissue levels of AA, within the
context of a human equivalent diet, remains inconclusive.
The inconsistent use of n-3 and n-6 essential fatty
acids (EFAs) in the background of rodent diets is pervasive in the literature [5-10]. These EFAs are important
components of the Western diet and can impact the AA
phospholipid pool when absent or provided at insufficient quantities in the diet. Despite suggestions otherwise, a systematic review of the human literature reports
that increases in dietary LA do not appear to significantly modify AA levels in phospholipids of plasma/
serum or erythrocytes when supplemented to standard
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Western diets [11]. Therefore, if precise physiological
nutrient translation of fatty acids is desired, it may be
important for dietary aspects of the rodent model to
bear firm resemblance to human dietary components.
This study was designed to investigate a putative standard for allometric scaling with regards to an animal dietary design as it relates to the relationship between dietary
LA and tissue AA. This is the first study to examine the
physiological response of dietary LA on changes in AA
levels in plasma/serum or erythrocyte phospholipids when
provided at human equivalent supplemental doses within
the context of a Western background diet, based on a percentage of energy (i.e., metabolic activity). We further
investigated the potential contribution of dietary AA on
tissue AA content within the context of a Western-type
diet. This mathematical model using a surrogate of metabolic activity instead of differences in BW for allometric
scaling should better equate interspecies translation and
accommodate the differences in metabolic disparity
between rodents and humans.

Methods
Animals

Sixty-two C57BL/6J male mice (Harlan Laboratory,
Indianapolis, IN), 6-7 weeks of age, were randomly

assigned to nine dietary groups; 5-7 animals per group
were housed 2-3 animals per cage in a temperature controlled room with a 12 hr light-dark cycle. Prior to
sacrifice, animals were fasted overnight. All animal procedures were approved by the University of Tennessee
Animal Care and Use Committee in accordance with
NIH guidelines.
Diets

All animals were maintained on a control diet for one
week prior to being transferred to one of the experimental diets or maintained on the control diet. The
control diet was based on a US17 Monsanto diet with
slight modifications in macronutrient distributions
(Table 1). The diet was designed to mimic the Western diet with the following distribution (% of energy):
protein 16%, carbohydrates 50% and lipids 34%
(Research Diets, New Brunswick, NJ) [12]. Within the
lipid fraction, saturated, monounsaturated and polyunsaturated fats were designed to be provided at 13%,
14% and 7% of energy, respectively. The polyunsaturated fats LA, ALA, AA and EPA+DHA were provided
at 6%, 0.6%, 0.07% and 0.1% of energy, respectively.
These levels are similar to those suggested in the literature for humans on a Western diet [12,13] and/or

Table 1 Composition of the diets
Dietary Groups
Diet

1

2

3

4

5

6

7

8

9

-2%1 LA

Control

+2% LA

+4% LA

+6% LA

+8% LA

+0.23% AA

+0.45% AA

+1.36% AA

17.4
54.7

17.4
54.7

17.4
54.7

17.4
54.7

16.8

16.8

16.8

16.8
171

g/100 g
Protein
Carbohydrate

17.4
54.7

17.4
54.7

17.4
54.7

17.4
54.7

17.4
54.7

Lipid

16.8

16.8

16.8

16.8

16.8
g/kg

Casein
L-Cysteine
Corn Starch

171

171

171

171

171

171

171

171

3

3

3

3

3

3

3

3

3

337

337

337

337

337

337

337

337

337

Maltodextrin 10

85

85

85

85

85

85

85

85

85

Sucrose
Cellulose

114
57

114
57

114
57

114
57

114
57

114
57

114
57

114
57

114
57

Cocoa Butter, Deodorized

47.5

42.57

38.12

33.4

28.72

23.99

41.47

40.37

35.97

Flaxseed Oil

5.11

5.11

5.11

5.11

5.11

5.11

5.11

5.11

5.11

Palm Oil, Bleached, Deodorized

66.5

59.6

53.38

46.8

40.23

33.62

59.6

59.6

59.6

Safflower Oil, USP

17.75

32.35

32.35

32.35

32.35

32.35

32.35

32.35

32.35

Trisun Extra

34.2

30.65

27.46

24.06

20.69

17.29

30.65

30.65

30.65

-

-

14.6

29.30

43.90

58.60

-

-

-

Arachidonic Acid, Ethyl Ester
Eicosapentaenoic Acid, Ethyl Ester

0.40
0.17

0.40
0.17

0.40
0.17

0.40
0.17

0.40
0.17

0.40
0.17

1.10
0.17

2.2
0.17

6.6
0.17

Docosahexaenoic Acid, Ethyl Ester

0.27

0.27

0.27

0.27

0.27

0.27

0.27

0.27

0.27

Sunflower Oil

1

% change with regards to energy. In addition, the following were also included in the diet but are not listed above (g/1000 g): mineral mix S10026,11 g;
dicalcium phosphate, 15 g; calcium carbonate 6.2 g; potassium citrate, 1 H2O, 18.7 g; vitamin mix V13401, 11.4 g; alpha-tocopheryl acetate (500 IU/g), 0.1 g.
Abbreviations: AA, arachidonic acid; LA, linoleic acid
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supported by the DRIs for median daily intakes [14].
AA and EPA+DHA were provided as ethyl esters
(NuChek Prep, Elysian, MN). Experimental diets
remained isocaloric and were formulated using the
control diet as the background diet containing LA at
~6% of energy with additional adjustments in LA content (-2%, +2%, +4%, +6%, +8% of energy) with the
addition (or subtraction) of sunflower oil (70% w/w
LA) at the expense of cocoa butter, palm and trisun
oils based on the ratios found in the control diet. The
diets supplemented with AA were adjusted at the
expense of cocoa butter.
Water and food were provided ad libitum for 21-25
days. Fresh diets were provided daily and uneaten food
was discarded to minimize oxidation prior to consumption. Fatty acid analysis of the diets is presented in
(Table 2).
Fatty acid analysis

Animals were randomized on a 5 day sacrifice cycle.
Following 21-25 days on the experimental and control
diets, 0.5-1.0 ml of whole blood was collected via cardiac puncture under anesthesia (isofluorane inhalation)
using a tuberculin syringe with a 25 gauge needle containing an anticoagulant (3.8% trisodium citrate).
Whole blood was centrifuged at 660 × g for 4 min at
room temperature for separation of plasma and a pellet that was predominately erythrocytes, where each
fraction was subjected to lipid extraction. Three ml of
chloroform-methanol (1:2, v/v) were added to each

fraction, and lipids were extracted with chloroform (1
ml) plus saline (1 ml), followed by chloroform (1 ml)
(2×). The pooled chloroform extracts were evaporated
and resuspended in a small amount of chloroform
(~25 μL), and phospholipids were separated via thin
layer chromatography (TLC) using HPTLC plates precoated with silica gel 60 (Merck, Darmstadt, Germany)
using a chloroform-methanol (8:1, v/v) solvent system.
The phospholipids were recovered from the TLC plates
and saponified in 0.5 N NaCl and in the presence of
BF3 in methanol at 86°C. Fatty acid methyl esters were
extracted with equal volumes of hexane (2×) and
evaporated under nitrogen. Fatty acid methyl esters
were resuspended in hexane and analyzed by gas chromatography with a Hewlett-Packard 5880 gas chromatograph (Rochester, NY) using a DB23 capillary
column (0.25 mm × 30 m) (J and W Chromatography,
Folsom, OH) with hydrogen as the carrier gas, with
temperature programming from 160°C to 250°C at 3.5°
C/min The internal standard 1,2 diheptadecanoyl-snglycero-3-phosphocholine (17:0) (Avanti Polar Lipids,
Alabaster, AL) was added to each sample prior to lipid
extraction. The fatty acid methyl esters were identified
by comparing the retention times with those of known
standards (NuChek Prep, Elysian, MN). The fatty acids
are presented as mole %.
Statistical analysis

Phospholipid fatty acid content in plasma and erythrocytes were compared across treatment groups using a

Table 2 The fatty acid composition of the diets
Dietary Groups
1

2

3

4

5

6

7

8

9

2%

4%

6%

8%

0.23%

0.45%

1.36%

Control

LA

LA

LA

LA

AA

AA

AA

-2%1
Fatty Acids

1

LA
2

12:0
14:0

0.47
0.69

0.42
0.69

0.39
0.59

0.34
0.56

0.27
0.48

0.26
0.43

0.42
0.63

0.43
0.65

0.42
0.66

16:0

26.48

24.69

22.66

20.63

18.71

16.8

24.62

24.31

23.71

16:1

0.17

0.1

0.15

0.14

0.09

0.09

0.15

0.16

0.16

18:0

13.13

11.39

11.19

10.08

9.52

8.5

11.69

11.29

10.54

18:1n-9

42.44

40.44

38.44

36.62

35.00

33.06

40.11

39.79

39.00

18:2n-6

13.24

18.93

23.23

28.24

32.5

37.39

19.01

19.05

19.08

18:3n-3

1.78

1.79

1.77

1.8

1.77

1.8

1.78

1.84

1.83

20:0
20:1

0.58
0.14

0.54
0.17

0.52
0.15

0.49
0.15

0.48
0.17

0.44
0.14

0.55
0.16

0.55
0.17

0.51
0.14

20:4n-6

0.21

0.21

0.22

0.22

0.2

0.22

0.55

1.11

3.32

20:5n-3

0.09

0.03

0.08

0.07

0.06

0.1

0.05

0.09

0.06

22:0

0.31

0.31

0.34

0.37

0.42

0.46

0.31

0.29

0.30

22:6n-3

0.26

0.29

0.27

0.28

0.29

0.31

0.3

0.27

0.27

% change with regards to energy
2
g/kg diet
Abbreviations: AA, arachidonic acid; LA, linoleic acid.
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one-way analysis of variance (ANOVA), followed by
Tukey’s Honestly Significant Difference (HSD) post-hoc
test to determine significant differences between groups.
All data were tested for normality, homogeneity of variance, and for outliers. The data were evaluated by SPSS
18 statistical package (University of Tennessee, Knoxville, TN). Data was considered significant at p < 0.05.

Results
Food intake and weight gain were not statistically different between dietary groups (data not shown).
Fatty acid composition of plasma phospholipids

The composition of oleic acid and LA in plasma phospholipids tended to reflect differences in dietary levels
of these fatty acids; however, much of these effects were
not statistically significant (Figure 1 and Table 3). The

25
b

dietary group with the lowest levels of LA and highest
levels of oleic acid (group 1) had the lowest levels of LA
and highest levels of oleic acid in the plasma phospholipids, respectively. The levels of AA did not change in
any of the groups with increasing or decreasing levels of
dietary LA (Table 3). DHA levels were not different
among groups, with the exception of group 5. When
AA was supplemented to the diets, tissue AA levels progressively increased in a dose responsive manner at the
expense of LA (Figure 2 and Table 4), but tissue DHA
levels did not change. A summary of the effects of LA
and AA supplementation are provided in (Figure 1 and
Figure 2), respectively.
Fatty acid composition of erythrocyte phospholipids

The composition of oleic acid and LA in the phospholipids of erythrocytes reflected differences in dietary levels

b b

ab
ab

20

a

Mole %

15
-2 en% LA
Control

10

+2 en% LA
+4 en% LA
+6 en% LA
+8 en% LA

5

0

18:1n-9

18:2n-6

20:4n-6

Fatty Acids
Figure 1 Effects of increasing/decreasing dietary linoleic acid on changes in plasma/serum phospholipid fatty acid concentration. Mice
were fed background diets that mimicked the composition of a Western diet with increasing or decreasing levels (% change, based on energy)
of linoleic acid. The data (mole %) is presented as mean ± SD. Means with the same superscript within the same row (i.e., individual fatty acid)
are not statistically different at (p < 0.05). Groups of bars within each fatty acid without superscripts indicate no significant differences were
observed among groups. Abbreviations: LA, linoleic acid.
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Table 3 The fatty acid composition of plasma phospholipids from mice fed linoleic acid supplemented diets
Dietary Groups
Fatty Acid

1

2

3

4

5

6

-2% LA1

Control

+2% LA

+4% LA

+6% LA

+8% LA

16:0

33.54 ± 0.932

34.40 ± 0.80

33.60 ± 1.03

33.25 ± 0.96

35.29 ± 1.15

32.87 ± 0.88

18:0

13.68 ± 0.55

13.41 ± 0.31

13.07 ± 0.56

13.84 ± 0.61

13.97 ± 0.66

13.49 ± 0.54

18:1n-9

12.50 ± 0.50

11.69 ± 0.65

9.11 ± 0.64

9.23 ± 0.70

10.29 ± 1.26

10.10 ± 1.18

18:2n-6

17.80 ± 0.28a

19.22 ± 0.42ab

20.58 ± 0.44ab

21.86 ± 0.93b

22.15 ± 1.53b

22.46 ± 1.27b

20:4n-6

13.41 ± 0.40

12.74 ± 0.50

13.94 ± 0.84

13.39 ± 0.63

11.77 ± 0.75

13.10 ± 0.63

22:6n-3

9.07 ± 0.98a

8.54 ± 0.56ab

9.09 ± 0.60a

8.43 ± 0.59ab

6.53 ± 0.79b

7.99 ± 0.49ab

1

%change with regards to energy
Relative abundance (mol%) presented as mean ± SEM
ab
Means with the same superscript within the same row are not statistically different at p < 0.05, Tukey’s honestly significant difference.
Abbreviations: LA, linoleic acid
2

the diets, erythrocyte AA content, as well as that of its
metabolites 22:4 n-6 and 22:5 n-6 progressively
increased primarily at the expense of LA, but reductions
in dihomo-gamma-linolenic acid were also observed
(Table 6 and Figure 4). DHA levels were not reduced
with increasing levels of dietary AA.

of these fatty acids where LA supplementation significantly increased LA in the tissues (Table 5 and Figure 3).
Levels of dihomo-gamma-linolenic acid (20:3n-6) and
AA were unaffected by changes in dietary LA. Similarly,
DHA content in erythrocytes were unaffected by
changes in LA intake. When AA was supplemented in

a

20

ab

c
bc

bc
c

ab

15

Mole %

a

10

Control
+0.23 en% AA

+0.45 en% AA
+1.36 en% AA
5

0
18:1n-9

18:2n-6

20:4n-6

22:6n-3

Fatty Acids
Figure 2 Effects of increasing dietary arachidonic acid on changes in plasma/serum phospholipid fatty acid concentration. Mice were
fed background diets that mimicked the composition of a Western diet with increasing levels (% change, based on energy) of arachidonic acid.
The data (mole %) is presented as mean ± SD. Means with the same superscript within the same row (i.e., individual fatty acid) are not
statistically different at (p < 0.05). Groups of bars within each fatty acid without superscripts indicate no significant differences were observed
among groups. Abbreviations: AA, arachidonic acid.
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Table 4 The fatty acid composition of plasma
phospholipids from mice fed arachidonic acid
supplemented diets
Dietary Groups
2

7

8

9

Control

+0.23% AA1

+0.45% AA

+1.36% AA

16:0

34.40 ± 0.872

33.62 ± 0.82

33.71 ± 1.07

34.76 ± 0.81

18:0

13.41 ± 0.34

13.25 ± 0.42

13.34 ± 0.53

12.82 ± 0.36

18:1n-9
18:2n-6

11.69 ± 0.72 11.80 ± 0.83 11.69 ± 0.96 11.53 ± 0.94
19.22 ± 0.46a 18.88 ± 0.59ab 17.04 ± 0.28bc 15.47 ± 0.41c

20:4n-6

12.74 ± 0.54a 14.21 ± 0.66ab 15.94 ± 0.81bc 17.93 ± 1.00c

Fatty Acid

22:6n-3

8.54 ± 0.55

8.52 ± 0.52

8.28 ± 0.51

7.51 ± 0.45

1

%change with regards to energy
2
Relative abundance (mol%) presented as mean ± SEM
abc
Means with the same superscript within the same row are not statistically
different at p < 0.05, Tukey’s honestly significant difference.
Abbreviations: AA, arachidonic acid

Comparison of LA and AA data in the mouse to similar
data generated in human clinical trials

When the mouse data for LA was plotted against similar
data generated in human clinical trials based on %
energy [11], the results were similar between species
(Figure 5). When the mouse data for AA was plotted
against similar data generated in human clinical trials
based on % energy [11], the changes in AA levels in the
mice resembled the human data at the two lowest doses
but not at the highest dose (Figure 6).

Discussion
Animal models are not intended to replace humans,
but be a substitute that is often better controlled and
better able to answer narrow research questions that
could not be done, on a practical basis, with humans.
A common challenge faced by nutrition researchers

who are interested in interspecies comparisons is identifying an appropriate background diet and appropriate
doses for supplemented nutrients. In order to make
these choices, studies have to be performed that can
demonstrate human equivalent responses to ensure
translation between species. Without these fundamental studies, no guidelines can be formulated governing
scientific justification for dosing when extrapolation to
humans is desired. Currently, no guidelines exist for
appropriate dosing of dietary PUFAs for experimental
models (i.e., mice, rats) as they relate to humans and
their intakes. As such, the overall objective of this
research was to determine the extent to which supplementation of human equivalent doses of LA and AA
changed tissue AA content within the context of a
Western-type diet using a common experimental
rodent model. These results were then compared to
similar data generated from clinical trials with increasing and decreasing levels of dietary LA [11]. This is
the first known study of its kind.
Interspecies relationships of body mass and mammalian physiology have been explored for over a century
where various aspects of metabolism are proportional
to an exponent of body weight (W n ), with “n” being
between 0.67 and 0.75 [15-18]. Interspecies comparisons with regards to energetics were in part pioneered
by Brody and Kleiber where they described the nonlinear relationship between metabolic rate and body
mass as it relates to allometric scaling (as reviewed by
[19]). They described the concept that the relationship
between metabolic rate (MR) and body weight could
be linearized with the following equation: MR = a(W n)
(where “a“ is a proportionality constant, “W” is in Kg
and “n” is an exponent between 0.70 and 0.75). More
recently, Rucker and Storms (2002) elegantly described

Table 5 The fatty acid composition of erythrocytes phospholipids from diets supplemented with linoleic acid
Dietary Groups
Fatty Acid

1
-2% LA1

2
Control

3
+2% LA

4
+4% LA

5
+6% LA

6
+8% LA

16:0

34.19 ± 0.662

34.80 ± 0.63

34.40 ± 0.48

32.81 ± 0.69

34.67 ± 0.62

33.57 ± 0.71

18:0

13.77 ± 0.30

14.09 ± 0.52

15.45 ± 0.43

14.73 ± 0.45

14.18 ± 0.30

15.35 ± 0.57

18:1n-9

17.57 ± 0.40a

16.63 ± 0.46a

14.50 ± 0.34b

14.61 ± 0.21b

14.48 ± 0.28b

14.09 ± 0.31b

18:2n-6

a

b

b

bc

cd

14.52 ± 0.12d

10.69 ± 0.13

12.03 ± 0.23

12.23 ± 0.24

13.09 ± 0.48

13.72 ± 0.28

20:3n-6

1.18 ± 0.33

1.12 ± 0.04

1.22 ± 0.61

1.19 ± 0.08

1.18 ± 0.03

1.18 ± 0.06

20:4n-6

14.33 ± 0.54

13.60 ± 0.57

14.58 ± 0.45

15.12 ± 0.65

14.56 ± 0.41

13.66 ± 0.74

22:4n-6
22:5n-6

1.40 ± 0.05
0.40 ± 0.05

1.27 ± 0.13
0.45 ± 0.02

1.44 ± 0.10
0.50 ± 0.03

1.62 ± 0.13
0.58 ± 0.10

1.67 ± 0.06
0.55 ± 0.02

1.51 ± 0.10
0.47 ± 0.04

22:5n-3

0.70 ± 0.04

0.64 ± 0.04

0.60 ± 0.03

0.63 ± 0.05

0.60 ± 0.03

0.57 ± 0.05

22:6n-3

5.76 ± 0.34

5.37 ± 0.49

5.43 ± 0.20

5.64 ± 0.36

5.29 ± 0.27

4.99 ± 0.54

1

%change with regards to energy
Relative abundance (mol%) presented as mean ± SEM
abcd
Means with the same superscript within the same row are not statistically different at p < 0.05, Tukey’s honestly significant difference.
Abbreviations: LA, linoleic acid
2
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20
18

a
a

16

b b

b

b

bc cd

14
b

Mole %

12

d

b

a

-2 en% LA

10

Control
+2 en % LA

8

+4 en% LA
+6 en% LA

6

+8 en% LA

4
2
0
18:1n-9

18:2n-6

20:4n-6

Fatty Acids
Figure 3 Effects of increasing/decreasing dietary linoleic acid on changes in erythrocyte phospholipid fatty acid concentration. Mice
were fed background diets that mimicked the composition of a Western diet with increasing or decreasing levels (% change, based on energy)
of linoleic acid. The data (mole %) is presented as mean ± SD. Means with the same superscript within the same row (i.e., individual fatty acid)
are not statistically different at (p < 0.05). Groups of bars within each fatty acid without superscripts indicate no significant differences were
observed among groups. Abbreviations: LA, linoleic acid.

Table 6 The fatty acid composition of erythrocyte
phospholipids from diets supplemented with arachidonic
acid
Dietary Groups
Fatty Acid

1

2

7

8

9

Control

+0.23% AA1

+0.45% AA

+1.36% AA

16:0

34.80 ± 0.692

34.08 ± 0.86

34.43 ± 0.91

35.17 ± 0.95

18:0

14.09 ± 0.57

14.56 ± 0.31

14.03 ± 0.37

13.95 ± 0.34

18:1n-9

16.64 ± 0.50

16.49 ± 0.15

15.94 ± 0.29

15.62 ± 0.51

18:2n-6
20:3n-6

12.03 ± 0.25a 10.85 ± 0.16b
1.12 ± 0.05a 0.94 ± 0.01b

9.65 ± 0.18c
0.77 ± 0.02c

7.84 ± 0.07d
0.44 ± 0.01d

20:4n-6

13.60 ± 0.63a 15.13 ± 0.52ab 16.77 ± 0.53bc 18.71 ± 0.93c

22:4n-6

1.27 ± 0.15a

1.54 ± 0.09ab

1.90 ± 0.07bc

2.20 ± 0.11c

22:5n-6

a

0.45 ± 0.03

ab

ab

0.73 ± 0.05c

22:5n-3

0.64 ± 0.06

0.64 ± 0.03

0.65 ± 0.03

0.55 ± 0.04

22:6n-3

5.37 ± 0.54

5.28 ± 0.23

5.29 ± 0.37

4.78 ± 0.40

0.49 ± 0.02

0.57 ± 0.04

%change with regards to energy
2
Relative abundance (mol%) presented as mean ± SEM
abcd
Means with the same superscript within the same row are not statistically
different at p < 0.05, Tukey’s honestly significant difference.
Abbreviations: AA, arachidonic acid

the pitfalls of using differences in body weight as a
means of making interspecies extrapolations for micronutrients because of these non-linear relationships [20].
They addressed the appropriateness of several mathematical approaches to extrapolate nutrient intake
between mice and humans and suggested food (energy)
intake rather than body weight should be used to extrapolate nutrients for interspecies comparisons [20,21].
Interestingly, when this concept was applied to a variety
of standardized semi-purified diets (i.e., AIN76A,
AIN93G, AIN93M), extrapolations of the micro- and
macronutrients (i.e., PUFA) better mimicked recommended intakes (i.e., the DRIs) when based on energy
differentials as compared to body weight (Table 7 and
Table 8). This provided the rationale, if not a scientific
justification, for the background diet and doses used in
this study.
With this in mind, we generated a “human equivalent” background diet where the macronutrient composition mimicked that of the human diet when based
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20

c
bc
ab

15

a
a

Mole %

b
c

10

Control
d

+.23 en% AA
+.45 en% AA
+1.36 en% AA

5

0
18:1n-9

18:2n-6

20:4n-6

22:6n-3

Fatty Acids
Figure 4 Effects of increasing dietary arachidonic acid on changes in erythrocyte phospholipid fatty acid concentration. Mice were fed
background diets that mimicked the composition of a Western diet with increasing levels (% change, based on energy) of arachidonic acid. The
data (mole %) is presented as mean ± SD. Means with the same superscript within the same row (i.e., individual fatty acids) are not statistically
different at (p < 0.05). Groups of bars within each fatty acid without superscripts indicate no significant differences were observed among
groups. Abbreviations: AA, arachidonic acid.

on energy (Table 9) and evaluated the impact of dietary LA (4%-14% of energy) and AA (0.08%-1.35% of
energy) on changes in tissue AA levels in plasma and
erythrocyte phospholipids. These amounts translate
into human equivalent levels of 9-31 g/d and 0.18-2.7
g/d of LA and AA, respectively, and are within those
ranges reported in the DRIs for humans and/or used
in clinical trials [14,22]. Importantly, as opposed to
rodent diets that selectively provide only one or two of
the essential fatty acids (EFAs) (i.e., corn oil or soybean
oil based diets), our background diet contained all the
major n-6 and n-3 PUFAs found in the human diet (i.
e., LA, ALA, AA and long chain n-3 PUFA). This is
critical as all of these fatty acids are found in the Western diet and can have an impact on tissue AA levels.
For this reason, there has been great interest placed
upon n-6 PUFA metabolism, particularly when all
EFAs are sufficiently provided in the diet at human
equivalent levels.

The rodent model has been the superior target for
investigation of specific fatty acids and downstream
metabolites on tissue fatty acid composition since 1963
when Mohrhauer and Holman explored the metabolism
of dietary EFAs [7]. In this classic and highly cited
paper, rodents were initially fed a fat-free diet (i.e. with
the exclusion of all EFAs) prior to supplementation with
LA (ethyl linoleate) up to 5% from energy, where a
721% increase in liver AA composition was observed
with the highest doses. Other studies recapitulated these
earlier results when LA was provided to a background
diet that lacked nearly all or completely all n-3 and n-6
PUFAs [9,10]. When LA was increased from nearly 0%
of energy to 6-7% of energy in rodents, liver AA composition increased 173%-518% [6,8]. Increasing LA from
6% of energy to 27% of energy (or a human equivalent
dose of 59 g/d) resulted in a 134% increase in tissue AA
composition [5]. The addition of LA at supra-physiological doses (i.e., 17.3% of energy) from a background diet
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Figure 5 Comparison of LA data in the mouse to similar data generated in human clinical trials; increasing levels of supplemented LA
(% change based on energy) on changes in plasma/serum AA content. The changes in AA levels of plasma phospholipids from this study
(red squares) were plotted against archival data from human clinical trials (blue diamonds) (used with permission, see ref. 11). Abbreviations: AA,
arachidonic acid; LA, linoleic acid; PL phospholipids.

containing 7% LA, increased AA content by 375% when
no other EFAs were provided [10]. However, when
more moderate levels of LA were supplemented to a
diet containing human equivalent levels (i.e., 6.6% to
13.2% of energy), AA content in liver phospholipids
increased a modest 6% [8]. Notably, tissues have a
requirement for unsaturated fatty acids for structural
function and to help maintain membrane fluidity. When
animals are fed a diet that exclusively contains a single
PUFA (i.e., LA), its selective and robust conversion to a
more highly unsaturated form is not surprising. These
findings underscore the differential impact of dietary LA
in rodent diets on changes in tissue AA content when
the background diet is devoid of LA and/or other
PUFAs, or providing LA at doses approaching pharmacological levels.
What is an appropriate background diet in rodents
and what is an appropriate dose of LA that has

translational ability to humans? This would be dependent upon the human literature; that is, what is the
effect of LA on changes in tissue AA in individuals consuming a typical Western diet? The DRI (observed median intakes in the US population) for LA is 12 g/d and
17 g/d for women and men, respectively (approximately
6% of energy) [14]. In a recent review of the literature,
decreasing LA content in the diet up to 90% or increasing the levels up to 550% was not associated with
changes in AA content in the phospholipid pools of
human plasma/serum (see Figure 5) or erythrocytes
[11]. It is not unreasonable to think that with a background diet containing LA, ALA, AA, and long-chain n3 PUFAs (i.e., EPA and DHA) at typical intakes, modifying LA levels may not influence tissue AA levels in
these populations. Hence, in order to establish a human
equitable response to dietary LA on tissue AA composition in the rodent model, it seems best accomplished
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Figure 6 Comparison of AA data in the mouse to similar data generated in human clinical trials; increasing levels of supplemented
AA (% change based on energy) on changes in plasma/serum AA content. The changes in AA levels of plasma phospholipids from this
study (red squares) were plotted against archival data from human clinical trials (blue diamonds) (used with permission, see ref. 11).
Abbreviations: AA, arachidonic acid; PL phospholipids.

when all EFAs are present in the diet, especially for
results that are expected to translate proportionally to
humans.
Increasing LA from 0% to 2% of energy replete tissue
pools of n-6 PUFAs by increasing AA phospholipid concentrations [23]. Intake of LA above 2-3% of energy in
humans is not reportedly accompanied by an increase in
AA content in plasma or erythrocyte phospholipids
[22,24-29], results consistent with our data. Poor conversion rates in humans would account for these results
where the estimated fractional conversion of LA to AA
in adults was between 0.3% and 0.6% [30]. In rodents,
tracer kinetic analysis demonstrated greater efficiency of
C20 fatty acids in conversion to downstream end-products relative to C18 precursors [31]. This would imply
that feedback inhibition of Δ-6 desaturase, the rate limiting step in the conversion of LA to AA, may be
responsible. Likewise, the present study reports no significant alteration in plasma/serum or erythrocyte AA

phospholipids at the lowest supplemental dose of LA
(4% of energy) or the highest supplemental dose (14% of
energy). These results are supported by prior rodent
dietary studies supplementing LA at similar levels (6.8%
and 8.7% of energy) to a background diet already containing LA (4.5% of energy) [32,33]. Hence, supplementation of HEDs of LA to a background rodent diet
consisting of all EFAs found in the human diet (including LA and AA), results in changes in tissue AA content
that more accurately reflect those measured in humans
consuming similar levels [22,24-26,29].
Additionally, our data demonstrate the observable
inverse relationship of dietary AA and changes in tissue
LA within the rodent model. When AA was supplemented to rodents consuming a Western-like diet, tissue AA
content increased in a dose dependent manner, suggesting the lack of changes with LA supplementation was
not due to saturation of AA in the phospholipid pools
analyzed. Likewise, when dietary AA was provided to
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Table 7 Allometric scaling of micronutrients in an
AIN93G rodent diet based on differences in daily caloric
consumption or body weight (kg) as compared to the
daily recommended intakes for humans (DRI)
Nutrient

DRI

Kcal

BW

Thiamin

1.2 mg

15 mg

49 mg

Table 9 Allometric scaling of macronutrients in the US
diet and the background diet of the mice used in this
study based on caloric consumption
US Diet

Rodent Diet

%en; (g/d)

%en; (HED, g/d)

Macronutrients
Riboflavin

1.3 mg

2.7 mg

55 mg

Protein

16%

16%

B6

1.3 mg

3.0 mg

52 mg

Niacin

16 mg

15 mg

273 mg

Carbohydrate
Lipids

50%
34%

50%
34%

Biotin

30 μg

101 μg

1820 μg

SFA

13%

13%

Folate

400 μg

1001 μg

18200 μg

MUFA

14%

14%

Viatmin E
Vitamin A

15 mg
900 mg

38 mg
605 mg

683 mg
10,929 mg

PUFA

7%

7%

Calcium

1000 mg

2601 mg

46,992 mg

Polyunsaturated Fatty Acids

Magnesium

400 mg

255 mg

4614 mg

Iron

8 mg

17 mg

315 mg

Manganese

2.3 mg

29 mg

533 mg

18:2 n-6
18:3 n-3

6.3%
0.6%

6.3% (14 g)
0.6% (1.3 g)

Selenium

55 μg

123 μg

2229 μg

20:4 n-6

0.07%

0.07% (155 mg)

Iodine

150 μg

105 μg

1893 μg

20:5 n-3

0.034%

0.034% (75 mg)

Zinc

11 mg

15 mg

266 mg

22:6 n-3

0.054%

0.054% (125 mg)

The data applies for a 25 g mouse consuming 15 Kcal/d and a 70 Kg human
consuming 2000 Kcal/d. The conversion factor is 134 for calories (Kcal) and
2800 for body weight (BW).

rodents (mice, hamsters) at 1.5-4% of energy, AA content in hepatic phospholipids increased 21-80%;
[12,32-34]. Similar results were observed in intestines,
macrophages, lung, heart, spleen, kidneys, testes and
platelets [12,32,33]. These results are comparable to

Table 8 Allometric scaling of linoleic acid and alphalinolenic acid in an AIN93G, AIN93M and AIN76A rodent
diet based on differences in daily caloric consumption
(Kcal) or body weight (BW) (in kg) as compared to the
Adequate Intakes (AI) from the daily recommended
intakes for humans (DRI)
Rodent Diet Fatty Acid

AI (DRI)

Kcal

BW

Linoleic acid

12-17 g

20 g

423 g

Alpha-linolenic acid

1.1-1.6 g

2.6 g

55 g

12-17 g
1.1-1.6 g

12 g
1.6 g

242 g
31 g

Linoleic acid

2-17 g

15.6 g

336 g

Alpha-linolenic acid

1.1-1.6 g

0g

0 mg

AIN93Ga

AIN93Mb
Linoleic acid
Alpha-linolenic acid
AIN76Ac

The data applies for a 25 g mouse consuming 15 kcal/d and a 70 Kg human
consuming 2000 Kcal/d.
a
Based on a diet containing 7% (w/w) soybean oil that is 54% linoleic acid
and 7% a-linolenic acid.
b
Based on a diet containing 4% (w/w) soybean oil that is 54% linoleic acid
and 7% a-linolenic acid.
c
Based on a diet containing 5% (w/w) corn oil that is 60% linoleic acid.

Abbreviations: HED, human equivalent dose.

humans [11]; however, the response in rodents is more
modest than that observed in humans supplemented
with AA at the highest dose (see Figure 6) [11]. The
estimated human intake for AA is <200 mg/day [4]. Our
highest supplemented dose of 1.35% of energy (or a
HED of 3 g/d) increased phospholipid AA levels in
plasma/serum by 40%, while providing a dose of 0.751.5 g/d in humans increased tissue AA content by ~85%
[35,36] with a maximum change of 136% at a dose of 6
g/d [37]. Rodents, compared to humans, have higher
requirements for the more highly unsaturated fatty acid
DHA in their tissue phospholipids [38]. This may preclude the need for higher levels of AA in tissues,
accounting for the more modest effects observed in
rodents following AA supplementation. Of importance,
these changes in AA content were always at the expense
of tissue LA, suggesting that dietary AA targets the
same phospholipid pool occupied by LA [12,32,33]. This
relationship between the changes in tissue levels of AA
and LA following AA supplementation is supported by
human clinical data [35]. The inverse is not always true.
While some studies suggest an inverse relationship
exists between tissue LA and AA levels when LA is supplemented in the diet [11,25,28], these studies are in the
minority.

Conclusions
Currently there are no guidelines providing assistance
as to how to formulate a human equivalent diet for
rodents to improve translation of data to humans. The
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overall intent of this research was to test a theoretical
model for allometric scaling based on energy differences between species. We chose the relationship
between dietary LA and its effects on tissue AA content as a testable target. We wanted to determine the
extent to which supplementation with human equivalent doses of LA and AA changed tissue AA content
within the context of a Western-type diet using a common experimental rodent model. We proposed that
providing animals a background diet that mimicked
the Western diet with regards to macro- and micronutrients and fatty acid profiles, and supplementing LA
at human equivalent doses, we could observe a human
equivalent response with regard to changes in AA
levels in plasma/serum and erythrocyte phospholipids.
Our results recapitulated those in humans and provide
support for the concept that allometric scaling between
species for dietary LA can be accomplished based on
energy and metabolic differences. It is important to
note that these results cannot be extrapolated to all
tissues.
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